💊 Gabapentin Dosage Reference

Gabapentin for neuropathic pain typically starts at 300 mg on day 1, 300 mg twice daily on day 2, 300 mg three times daily on day 3, then titrates toward 1,800-3,600 mg/day in divided doses. Kidney impairment lowers the range: at CrCl 30-59 it is 400-1,400 mg/day. Select your indication and kidney function for the reference range.

How to Use This Reference

This is an educational summary of standard labeling and guidelines, not a prescription. Gabapentin is cleared by the kidneys unchanged, so renal function drives dosing.

Standard Dosing by Kidney Function

Gabapentin is not metabolized: it is excreted unchanged in urine, so half-life stretches from 5-7 hours to days as kidneys fail, and the dose must shrink proportionally. The titration exists because starting at full dose causes intolerable sedation and dizziness; the day-1-2-3 ramp is the labeled approach, though many clinicians titrate even more gradually in older adults. Doses above 1,800 mg/day help a minority, but the label maximum is 3,600 mg/day, and absorption saturates at higher doses (bioavailability falls as dose rises), which is why splitting into three doses matters.

Worked Example

A 68-year-old with postherpetic neuralgia and CrCl 40: range 400-1,400 mg/day in two divided doses. A reasonable course: 300 mg at bedtime for several days, then 300 mg twice daily, reassessing pain and sedation at each step, aiming for the lowest dose that controls pain, often 600-900 mg/day total in this kidney band. A 40-year-old with normal kidneys and diabetic neuropathy: standard titration to 900 mg/day (300 mg TID) initially, increasing by 300 mg/day every few days as tolerated toward 1,800 mg/day. Many patients find their effective dose well below the maximum; the goal is pain control with tolerable side effects, not the top of the range. The calculator maps CrCl to these labeled bands.

What Gabapentin Is (and Is Not) For

Expectations matter: gabapentin helps roughly 1 in 7-8 people with postherpetic neuralgia achieve 50% pain reduction (the NNT), which is worth trying but not a promise. It does not work for nociceptive pain (sprains, headaches), and perioperative use has fallen out of favor after trials showed little benefit with real harms. For nerve-pain context, our fatigue scale tracks a common comorbidity, and our GAD-7 screens the anxiety that amplifies chronic pain.

Safety Essentials

Sedation, dizziness, and ataxia are dose-dependent and worse in older adults: fall risk is the practical concern, so dose at night first and rise slowly. Do not stop abruptly after sustained use; taper over at least a week to avoid withdrawal (agitation, sweating, rebound pain). Combined with opioids, gabapentinoids raise overdose risk substantially; the FDA warns against the combination without careful supervision. Misuse exists (euphoria at high doses), and several states now monitor it. In pregnancy, discuss risks with your obstetrician; in the elderly, start low and go slow is not a suggestion.

Talking to Your Prescriber

Bring three things to the visit: your pain pattern (burning, shooting, allodynia suggest neuropathic), your kidney numbers, and your full medication list (especially opioids, sleep aids, and alcohol use). Ask what target dose and timeline they have in mind, what side effects should make you call, and what the taper plan is if it does not help. A time-limited trial (4-6 weeks at a therapeutic dose) with a predefined stop rule beats open-ended prescribing.

Gabapentin in Older Adults

Aging changes gabapentin's risk-benefit balance in two ways: kidneys clear it more slowly, and brains tolerate it less well. Creatinine clearance falls with age even when serum creatinine looks normal (less muscle makes less creatinine), so a 78-year-old with a "normal" creatinine of 1.0 may have a CrCl under 50 and need the reduced band without anyone flagging it. Meanwhile sedation, dizziness, and ataxia hit harder, and the resulting falls can cost more than the pain being treated. The geriatric approach is start low and go slow: 100 mg at bedtime, increase no faster than every 3-7 days, and reassess the indication at every visit because drugs started for acute shingles pain often continue for years without review. Watch for cognitive dulling that patients attribute to aging and families attribute to dementia; a gabapentin taper sometimes reverses it. Deprescribe when the pain has resolved or the drug never helped: taper over weeks, not days, in long-term users.

For informational purposes only, not medical advice. Consult a healthcare professional.